

P&T Motion History Targeted Immune Modulators (TIMs)

Drugs reviewed	Motion	Date reviewed	Surveillance accepted as adequate	Reiteration of prior motion	Decision
abatacept adalimumab anakinra* apremilast baricitinib* bimekizumab brodalumab certolizumab pegol deucravacitinib etanercept golimumab guselkumab infliximab ixekizumab natalizumab* ozanimod* risankizumab rituximab* roflumilast sarilumab* secukinumab spesolimab tildrakizumab tocilizumab* tofacitinib upadacitinib ustekinumab	<p>TIMs for Plaque Psoriasis, Psoriatic Arthritis, and Generalized Pustular Psoriasis</p> <p>After considering the evidence of safety, efficacy, effectiveness and special populations for the use of targeted immune modulators for their FDA approved indications relative to Plaque Psoriasis, Psoriatic Arthritis, and Generalized Pustular Psoriasis. I move that: abatacept, adalimumab, apremilast, bimekizumab, brodalumab, certolizumab pegol, deucravacitinib, etanercept, golimumab, guselkumab, infliximab, ixekizumab, risankizumab, roflumilast, secukinumab, spesolimab, tildrakizumab, tofacitinib, upadacitinib, and ustekinumab are efficacious for their approved indications, including their applicable biosimilars when available. The PDL must include a drug approved for treatment of the following FDA indications (Plaque Psoriasis, Psoriatic Arthritis, and Generalized Pustular Psoriasis) and must include a self-administered agent if indicated.</p> <p>These medications cannot be subject to therapeutic interchange in the Washington preferred drug list.</p> <p>Motion: Flynn 2nd: Beste</p>	April, 17 2024	NA	No	Passed unanimous

Bold = new this update

Grey= not reviewed

*=drugs not reviewed, but carried forward from previous review

4/25/2024

P&T Motion History Targeted Immune Modulators (TIMs)

vedolizumab*					
abatacept adalimumab anakinra apremilast baricitinib brodalumab certolizumab pegol etanercept golimumab guselkumab infliximab ixekizumab natalizumab ozanimod risankizumab rituximab sarilumab secukinumab tildrakizumab tocilizumab tofacitinib upadacitinib ustekinumab vedolizumab	<p>TIMs for Crohn Disease and Ulcerative Colitis and Rheumatoid Arthritis and Ankylosing Spondylitis</p> <p>After considering the evidence of safety, efficacy, effectiveness and special populations for the use of targeted immune modulators for their FDA approved indications relative to rheumatoid arthritis, ankylosing spondylitis, Crohn Disease and Ulcerative Colitis. I move that: abatacept, adalimumab, anakinra, baricitinib, certolizumab pegol, etanercept, golimumab, infliximab, natalizumab, ozanimod, Risankizumab, rituximab, sarilumab, secukinumab, tocilizumab, tofacitinib, upadacitinib, ustekinumab, vedolizumab are efficacious for their approved indications, including their applicable biosimilars when available. The PDL must include a drug approved for treatment of the following FDA indications (rheumatoid arthritis, ankylosing spondylitis, Crohn Disease and Ulcerative Colitis) and must include a self-administered agent if indicated.</p> <p>These medications cannot be subject to therapeutic interchange in the Washington preferred drug list.</p> <p>Motion: Beste</p>	June 21, 2023	RA & AP Chawla Davydow accepted	No	Passed unanimous

Bold = new this update

Grey= not reviewed

*=drugs not reviewed, but carried forward from previous review

4/25/2024

**P&T Motion History
Targeted Immune Modulators (TIMs)**

	2 nd : Weiland				
--	---------------------------	--	--	--	--

Bold = new this update

Grey= not reviewed

*=drugs not reviewed, but carried forward from previous review

4/25/2024